Rhythm Pharmaceuticals (RYTM) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need for Capital

1. 01We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations
2. 02Our Revenue Interest Financing Agreement with Healthcare Royalty Partners could restrict our ability to commercialize IMCIVREE, limit cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operations
3. 03costs, following the achievement of a specified amount of cumulative net sales of IMCIVREE between July 1, 2022 and September 30, 2023

Risks Related to the Development of Setmelanotide and Other Product Candidates and our CHI Program

1. 04Interim, “topline” and preliminary data from our preclinical and clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
2. 05From time to time, we may also disclose real-world data from early access programs in particular patient cohorts, which are not controlled trials and may not be predictive of future results
3. 06The exclusive license agreement with LGC is important to our business. If we or LGC fail to adequately perform under the agreement, the development of bivamelagon could be delayed, or if we or LGC terminate the agreement, we would lose our rights to develop and commercialize bivamelagon
4. 07The number of patients with each of the MC4R pathway variants we are targeting is small and has not been established with precision. If the actual number of patients is smaller than we estimate, our revenue and ability to achieve profitability may be materially adversely affected
5. 08The clinical response rate used in this calculation is based on the clinical data currently available to us from our trials and may change as more data become available
6. 09We believe that the patient populations in the EU are similar to those in the United States. However, we do not have comparable epidemiological data from the EU and these estimates are therefore based solely on applying relative population percentages to the Company-derived estimates described above
7. 10If we experience delays or difficulties in the enrollment and/or retention of patients in clinical trials, our regulatory submissions or receipt of additional marketing approvals could be delayed or prevented
8. 11Failures or delays in the commencement or completion of our planned clinical trials could result in increased costs to us and could delay, prevent or limit our ability to generate revenue, achieve profitability and continue our business
9. 12If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted
10. 13Setmelanotide, RM-718 or bivamelagon may cause undesirable side effects that could delay or prevent additional regulatory approvals, limit the commercial profile of approved labeling, or result in significant negative consequences following marketing approval
11. 14We may not be able to obtain or maintain orphan drug designations for setmelanotide, RM-718 or bivamelagon or to obtain or maintain orphan exclusivity. Even with exclusivity, competitors may obtain approval for different drugs that treat the same indications as setmelanotide, RM-718 and bivamelagon
12. 15Product developers that benefit from PRIME designation may be eligible for accelerated assessment (in 150 days instead of 210 days), which may be granted for medicinal products of major interest from a public health perspective or that target an unmet medical need, but this is not guaranteed

Risks Related to the Commercialization of IMCIVREE and, if Approved, our Products Candidates

1. 16authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and provide reimbursement
2. 17If we are unable to establish, maintain or expand our sales, marketing and distribution capabilities or enter into agreements with third parties to market, sell, and distribute IMCIVREE, we may not be able to generate revenue
3. 18We may never receive regulatory approval to market setmelanotide outside of the United States, Canada, the European Union and the United Kingdom
4. 19We may not achieve or maintain market acceptance for IMCIVREE, which would limit the revenue that we generate from the sale of IMCIVREE
5. 20Our industry is intensely competitive. If we are not able to compete effectively against current and future competitors, we may not be able to generate revenue from the sale of IMCIVREE, our business will not grow and our financial condition and operations will suffer
6. 21We face potential product liability exposure, and, if claims are brought against us, we may incur substantial liability
7. 22We rely completely on third-party suppliers to manufacture our clinical and commercial drug supplies of setmelanotide, RM-718, and bivamelagon, and we intend to rely on third parties to produce preclinical, clinical and commercial supplies of any future product candidate
8. 23In light of our election to terminate the exclusive license agreement with RareStone Group Ltd., or RareStone, the development of setmelanotide in certain indications and commercialization of IMCIVREE in certain markets could be delayed or terminated and our business could be adversely affected

Risks Related to Our Intellectual Property Rights

1. 24If we are unable to adequately protect our proprietary technology or maintain issued patents directed to setmelanotide, RM-718, and bivamelagon, others could compete against us sooner, which could have a material adverse impact on our business, results of operations, financial condition and prospects
2. 25and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability
3. 26We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful
4. 27We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing IMCIVREE or our other product candidates
5. 28We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
6. 29Issued patents covering setmelanotide or our other product candidates could be found invalid or unenforceable if challenged in court
7. 30We do not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection
8. 31We are dependent on licensed intellectual property. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing setmelanotide or bivamelagon
9. 32Any termination could result in our loss of the right to use the licensed intellectual property, which could materially adversely affect our ability to develop and commercialize setmelanotide or bivamelagon, as well as harm our competitive business position and our business prospects
10. 33If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign legislation by extending the patent terms and obtaining product exclusivity for setmelanotide and our other product candidates, our business may be materially harmed
11. 34Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products
12. 35We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers

Risks Related to Regulatory Approval and Marketing of Setmelanotide and Other Legal and Compliance Matters

1. 36Future regulatory legislation or regulation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates
2. 37substantially revised before adoption, which is not anticipated before early 2026. The revisions, may, however, have a significant impact on the pharmaceutical industry and our business in the long term
3. 38Current and future healthcare reform legislation or regulation may increase the difficulty and cost for us and any future collaborators to commercialize setmelanotide and may adversely affect the prices we, or they, may obtain and may have a negative impact on our business and results of operations
4. 39Since its enactment, certain provisions of the ACA have been subject to judicial, executive, and legislative challenges and may be subject to additional challenges in the future
5. 40The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
6. 41decide not to directly promote or market our products, inappropriate activity by our international distribution partners could have implications for us
7. 42Our employees may engage in misconduct or other improper activities, whether knowingly or unknowingly, including violating applicable regulatory standards and requirements or engaging in insider trading, which could significantly harm our business
8. 43Actual or perceived failure to comply with data protection, privacy and security laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results
9. 44Our future growth depends, in part, on our ability to continue to penetrate foreign markets, where we will be subject to additional regulatory burdens and other risks and uncertainties
10. 45Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling setmelanotide or our other product candidates outside of the United States and require us to develop and implement costly compliance programs
11. 46Following a national referendum and enactment of legislation by the government of the UK, the UK formally withdrew from the EU on January 31, 2020
12. 47our ability to generate revenue and achieve or sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in Great Britain for our product candidates, which could significantly and materially harm our business

Risks Related to Employee Matters and Managing Growth

1. 48Our future success depends on our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel
2. 49We will need to develop and expand our Company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations
3. 50in legal claims or proceedings and liability under state, federal and international privacy laws, disruption of our operations, and damage to our reputation, which could adversely affect our business

Risks Related to Our Common Stock

1. 51Our directors and executive officers and their affiliated entities own a significant percentage of our stock and, if they choose to act together, will be able to exert significant influence over matters subject to stockholder approval
2. 52Market volatility may affect our stock price and the value of your investment
3. 53Our quarterly operating results may fluctuate significantly
4. 54Our ability to use certain net operating loss carryovers and other tax attributes may be limited
5. 55Substantial future sales or perceived potential sales of our common stock in the public market could cause the price of our common stock to decline significantly
6. 56We may be at an increased risk of securities litigation, including class action litigation
7. 57We do not intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock
8. 58Our common stock is subordinated to our Convertible Preferred Stock
9. 59Provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our Company or changes in our management and, therefore, depress the market price of our common stock
10. 60person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner
11. 61We have in the past and may in the future acquire businesses or products, form strategic alliances or create joint ventures in the future, and we may not realize their benefits
12. 62An active market for our common stock may not be maintained
13. 63If securities or industry analysts do not continue to publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline
14. 64Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights
15. 65Unfavorable global political or economic conditions could adversely affect our business, financial condition or results of operations
16. 66Business interruptions could adversely affect our operations
17. 67The increasing focus on environmental sustainability and social initiatives could increase our costs, harm our reputation and adversely impact our financial results
18. 68Short sellers of our stock may be manipulative and may drive down the market price of our common stock